“Also you need to have a monthly IV drip of donanemab or lecanemab, but don’t worry your make up skills will hide the bruising”
November 4, 2025 at 7:15 PM
“Also you need to have a monthly IV drip of donanemab or lecanemab, but don’t worry your make up skills will hide the bruising”
IMHO Trump will not make it through his second term.
I believe he’s been diagnosed with Alzheimer’s & is receiving treatment to slow the diseases progression.
Alzheimer’s patients receive lecanemab drug infusions (bruised hand) & have MRI’s per standard protocol.
www.tiktok.com/t/ZP8DfK7hN/
I believe he’s been diagnosed with Alzheimer’s & is receiving treatment to slow the diseases progression.
Alzheimer’s patients receive lecanemab drug infusions (bruised hand) & have MRI’s per standard protocol.
www.tiktok.com/t/ZP8DfK7hN/
November 5, 2025 at 12:36 PM
IMHO Trump will not make it through his second term.
I believe he’s been diagnosed with Alzheimer’s & is receiving treatment to slow the diseases progression.
Alzheimer’s patients receive lecanemab drug infusions (bruised hand) & have MRI’s per standard protocol.
www.tiktok.com/t/ZP8DfK7hN/
I believe he’s been diagnosed with Alzheimer’s & is receiving treatment to slow the diseases progression.
Alzheimer’s patients receive lecanemab drug infusions (bruised hand) & have MRI’s per standard protocol.
www.tiktok.com/t/ZP8DfK7hN/
Alzheimer’s disease is the most common cause of dementia, and currently there’s no cure. Could Lecanemab, recently approved by Health Canada, change the game? @jeyantvo.bsky.social asks neuroscientist Saskia Sivananthan (@brainwell.bsky.social, @mcgillfamilymed.bsky.social) tonight at 8pm
November 4, 2025 at 9:28 PM
Alzheimer’s disease is the most common cause of dementia, and currently there’s no cure. Could Lecanemab, recently approved by Health Canada, change the game? @jeyantvo.bsky.social asks neuroscientist Saskia Sivananthan (@brainwell.bsky.social, @mcgillfamilymed.bsky.social) tonight at 8pm
MRI is also used to monitor Alzheimer’s plaques, which would definitely explain the bruised hands.
Good chance Trump is taking Lecanemab to slow Alzheimer’s progression.
It’s given by IV every 2 weeks and has to be monitored by MRI to check for side effects like microbleeds and brain swelling.
Good chance Trump is taking Lecanemab to slow Alzheimer’s progression.
It’s given by IV every 2 weeks and has to be monitored by MRI to check for side effects like microbleeds and brain swelling.
November 3, 2025 at 4:05 AM
MRI is also used to monitor Alzheimer’s plaques, which would definitely explain the bruised hands.
Good chance Trump is taking Lecanemab to slow Alzheimer’s progression.
It’s given by IV every 2 weeks and has to be monitored by MRI to check for side effects like microbleeds and brain swelling.
Good chance Trump is taking Lecanemab to slow Alzheimer’s progression.
It’s given by IV every 2 weeks and has to be monitored by MRI to check for side effects like microbleeds and brain swelling.
Lecanemab is an FDA-approved monoclonal antibody infusion for early-stage Alzheimer’s disease. It requires regular MRIs to monitor for serious side effects like brain swelling or brain bleeding, both of which I wish for Trump.
October 30, 2025 at 9:48 PM
Lecanemab is an FDA-approved monoclonal antibody infusion for early-stage Alzheimer’s disease. It requires regular MRIs to monitor for serious side effects like brain swelling or brain bleeding, both of which I wish for Trump.
Discovered something interesting in a Canadian medical story. CA just approved lecanemab already approved in US for Alzheimer’s. Administered by intravenous and needs MRI monitoring. Hmm...
October 29, 2025 at 3:26 PM
Discovered something interesting in a Canadian medical story. CA just approved lecanemab already approved in US for Alzheimer’s. Administered by intravenous and needs MRI monitoring. Hmm...
New dementia drug explains all the MRIs.
"Lecanemab is taken by IV every two weeks. Patients are required to have an MRI before starting treatment, as well as four(4) MRIs during the first year to check for serious, but rare side effects, ..."
"Lecanemab is taken by IV every two weeks. Patients are required to have an MRI before starting treatment, as well as four(4) MRIs during the first year to check for serious, but rare side effects, ..."
CTV News – Breaking News and Video, Canada News Today
Get live updates on the latest local, national, and international news, including trusted reporting on politics, health, business, sports and more.
www.ctvnews.ca
October 29, 2025 at 7:06 AM
New dementia drug explains all the MRIs.
"Lecanemab is taken by IV every two weeks. Patients are required to have an MRI before starting treatment, as well as four(4) MRIs during the first year to check for serious, but rare side effects, ..."
"Lecanemab is taken by IV every two weeks. Patients are required to have an MRI before starting treatment, as well as four(4) MRIs during the first year to check for serious, but rare side effects, ..."
New dementia drug.
"Lecanemab is taken by IV every two weeks. Patients are required to have an MRI before starting treatment, as well as four(4) MRIs during the first year to check for serious, but rare side effects, ..."
"Lecanemab is taken by IV every two weeks. Patients are required to have an MRI before starting treatment, as well as four(4) MRIs during the first year to check for serious, but rare side effects, ..."
CTV News – Breaking News and Video, Canada News Today
Get live updates on the latest local, national, and international news, including trusted reporting on politics, health, business, sports and more.
www.ctvnews.ca
October 28, 2025 at 11:24 PM
New dementia drug.
"Lecanemab is taken by IV every two weeks. Patients are required to have an MRI before starting treatment, as well as four(4) MRIs during the first year to check for serious, but rare side effects, ..."
"Lecanemab is taken by IV every two weeks. Patients are required to have an MRI before starting treatment, as well as four(4) MRIs during the first year to check for serious, but rare side effects, ..."
If -Rump possibly was given an MRI for the Alzheimer’s drug lecanemab at Walter Reed on Oct 10th 2025, and was found to qualify for tx, it is usually given iv every 2 weeks. MRI’s are regular, betw 2nd and 3rd dosing. So if he’s on it, they’ll need an excuse for another MRI. Trips sure help hide it.
October 31, 2025 at 7:41 AM
If -Rump possibly was given an MRI for the Alzheimer’s drug lecanemab at Walter Reed on Oct 10th 2025, and was found to qualify for tx, it is usually given iv every 2 weeks. MRI’s are regular, betw 2nd and 3rd dosing. So if he’s on it, they’ll need an excuse for another MRI. Trips sure help hide it.
“Health Canada approved lecanemab (brand name Leqembi®) to treat people with a clinical diagnosis of mild cognitive impairment or early-stage Alzheimer's disease… This is the first disease-modifying Alzheimer's treatment approved for use in Canada.”
#Canada
#Canada
Health Canada Approves Lecanemab
The Alzheimer Society of Canada responds to Health Canada's decision to approve Alzheimer's disease medication lecanemab. Find information here about how this treatment works for people with mild cogn...
alzheimer.ca
October 28, 2025 at 11:15 AM
“Health Canada approved lecanemab (brand name Leqembi®) to treat people with a clinical diagnosis of mild cognitive impairment or early-stage Alzheimer's disease… This is the first disease-modifying Alzheimer's treatment approved for use in Canada.”
#Canada
#Canada
Excitement around Alzheimer’s treatment tempered by questions about efficacy, accessibility. Experts say lecanemab is an incremental benefit, not a cure. www.theglobeandmail.com/canada/artic... via @theglobeandmail.com
www.theglobeandmail.com/canada/artic... via @theglobeandmail.com #dementia
www.theglobeandmail.com/canada/artic... via @theglobeandmail.com #dementia
Excitement around Alzheimer’s treatment tempered by questions about efficacy, accessibility
Health Canada recently authorized use of lecanemab, but experts say the drug is an incremental benefit, not a cure
www.theglobeandmail.com
October 28, 2025 at 3:46 PM
Excitement around Alzheimer’s treatment tempered by questions about efficacy, accessibility. Experts say lecanemab is an incremental benefit, not a cure. www.theglobeandmail.com/canada/artic... via @theglobeandmail.com
www.theglobeandmail.com/canada/artic... via @theglobeandmail.com #dementia
www.theglobeandmail.com/canada/artic... via @theglobeandmail.com #dementia
An expensive new drug that can slow the progression of Alzheimer’s disease was approved by Health Canada on Friday.
While existing medications treat Alzheimer’s symptoms, lecanemab targets the disease’s underlying cause in order to reduce the rate of cognitive and functional decline
While existing medications treat Alzheimer’s symptoms, lecanemab targets the disease’s underlying cause in order to reduce the rate of cognitive and functional decline
‘An important milestone:’ Canada approves expensive new drug that can slow Alzheimer’s disease — CTV News
Health Canada has approved an expensive new drug that can slow the progression of Alzheimer’s disease.
apple.news
October 27, 2025 at 9:41 PM
An expensive new drug that can slow the progression of Alzheimer’s disease was approved by Health Canada on Friday.
While existing medications treat Alzheimer’s symptoms, lecanemab targets the disease’s underlying cause in order to reduce the rate of cognitive and functional decline
While existing medications treat Alzheimer’s symptoms, lecanemab targets the disease’s underlying cause in order to reduce the rate of cognitive and functional decline
Lecanemab a medication for dementia to slow progression and is administered by IV twice a month. The medication requires PET and MRI scans, just saying.
October 28, 2025 at 3:21 PM
Lecanemab a medication for dementia to slow progression and is administered by IV twice a month. The medication requires PET and MRI scans, just saying.
Full disclosure: I would love to take credit for discovering this info. I actually saw a post about Lecanemab so I looked it up and found it very interesting & plausible.
October 29, 2025 at 9:19 AM
Full disclosure: I would love to take credit for discovering this info. I actually saw a post about Lecanemab so I looked it up and found it very interesting & plausible.
When someone is getting Lecanemab infusions for early Alzheimer’s treatment, it requires routine MRI’s to assess for brain bleeds, etc
October 27, 2025 at 7:23 PM
When someone is getting Lecanemab infusions for early Alzheimer’s treatment, it requires routine MRI’s to assess for brain bleeds, etc
Name of the new Alzheimers drug is lecanemab, also known by its brand name Leqembi. Health 🇨🇦 approved this med which is 1st to target underlying cause of Alzheimers by clearing amyloid plaques from the brain + slowing the rate of cognitive + functional decline in people with early-stage disease.
October 28, 2025 at 4:01 AM
Name of the new Alzheimers drug is lecanemab, also known by its brand name Leqembi. Health 🇨🇦 approved this med which is 1st to target underlying cause of Alzheimers by clearing amyloid plaques from the brain + slowing the rate of cognitive + functional decline in people with early-stage disease.
www.ctvnews.ca/health/artic...
While existing medications treat Alzheimer’s symptoms, lecanemab is the first drug authorized in Canada that targets the disease’s underlying cause in order to reduce the rate of cognitive and functional decline.
While existing medications treat Alzheimer’s symptoms, lecanemab is the first drug authorized in Canada that targets the disease’s underlying cause in order to reduce the rate of cognitive and functional decline.
‘An important milestone:’ Canada approves expensive new drug that can slow Alzheimer’s disease
Health Canada has approved an expensive new drug that can slow the progression of Alzheimer’s disease.
www.ctvnews.ca
October 27, 2025 at 7:39 PM
www.ctvnews.ca/health/artic...
While existing medications treat Alzheimer’s symptoms, lecanemab is the first drug authorized in Canada that targets the disease’s underlying cause in order to reduce the rate of cognitive and functional decline.
While existing medications treat Alzheimer’s symptoms, lecanemab is the first drug authorized in Canada that targets the disease’s underlying cause in order to reduce the rate of cognitive and functional decline.
Routine MRIs are required when taking Lecanemab to slow the onset of Alzheimer’s. It is administered through IV and continued cognitive testing monitors progression. 🤔
October 27, 2025 at 4:50 PM
Routine MRIs are required when taking Lecanemab to slow the onset of Alzheimer’s. It is administered through IV and continued cognitive testing monitors progression. 🤔
Health Canada authorizes long-awaited drug to slow early-stage Alzheimer’s disease
https://www.byteseu.com/1489681/
TORONTO — Health Canada has authorized a drug shown to slow the progression of Alzheimer’s disease. Lecanemab is the first medication approved in Canada that targets the buildup …
https://www.byteseu.com/1489681/
TORONTO — Health Canada has authorized a drug shown to slow the progression of Alzheimer’s disease. Lecanemab is the first medication approved in Canada that targets the buildup …
Health Canada authorizes long-awaited drug to slow early-stage Alzheimer's disease - Bytes Europe
TORONTO — Health Canada has authorized a drug shown to slow the progression of Alzheimer’s disease.
www.byteseu.com
October 27, 2025 at 10:52 PM
Health Canada authorizes long-awaited drug to slow early-stage Alzheimer’s disease
https://www.byteseu.com/1489681/
TORONTO — Health Canada has authorized a drug shown to slow the progression of Alzheimer’s disease. Lecanemab is the first medication approved in Canada that targets the buildup …
https://www.byteseu.com/1489681/
TORONTO — Health Canada has authorized a drug shown to slow the progression of Alzheimer’s disease. Lecanemab is the first medication approved in Canada that targets the buildup …
Lecanemab Approved for Treatment of Early Alzheimer’s | alz.org share.google/KOp1escjEFJk.... I wouldn't be surprised if Trump is on this It requires an IV treatment every two weeks
Alzheimer's Association | Alzheimer's Disease & Dementia Help
Alzheimer's Association national site – get information on Alzheimer's disease and dementia symptoms, causes, treatment and care. Join the fight to end ALZ.
alz.org
October 10, 2025 at 1:39 AM
Lecanemab Approved for Treatment of Early Alzheimer’s | alz.org share.google/KOp1escjEFJk.... I wouldn't be surprised if Trump is on this It requires an IV treatment every two weeks
🧠 New analysis in @thelancet.com has shown, for the first time, that Alzheimer’s drugs lecanemab and donanemab can slow disease progression.
The anti-amyloid antibody medications allow patients to preserve functional independence.
@uclh.bsky.social @ucl.ac.uk @uclbrainscience.bsky.social
The anti-amyloid antibody medications allow patients to preserve functional independence.
@uclh.bsky.social @ucl.ac.uk @uclbrainscience.bsky.social
New medications for Alzheimer’s disease comparable in effectiveness to approved drugs in cancer, MS and arthritis
New medications for Alzheimer’s disease – which are not yet approved in some countries – have shown for the first time that clinical decline can be slowed with comparable effectiveness to approved med...
www.uclhospitals.brc.nihr.ac.uk
September 24, 2025 at 2:21 PM
🧠 New analysis in @thelancet.com has shown, for the first time, that Alzheimer’s drugs lecanemab and donanemab can slow disease progression.
The anti-amyloid antibody medications allow patients to preserve functional independence.
@uclh.bsky.social @ucl.ac.uk @uclbrainscience.bsky.social
The anti-amyloid antibody medications allow patients to preserve functional independence.
@uclh.bsky.social @ucl.ac.uk @uclbrainscience.bsky.social
🧠 Alzheimer's Treatment Update: New drugs may cause brain swelling/bleeding
Anti-amyloid-β (Aβ) monoclonal antibodies like lecanemab and donanemab are shifting Alzheimer's treatment from symptom management to disease modification. They show modest slowing of cognitive decline in early AD.
1/2
Anti-amyloid-β (Aβ) monoclonal antibodies like lecanemab and donanemab are shifting Alzheimer's treatment from symptom management to disease modification. They show modest slowing of cognitive decline in early AD.
1/2
September 21, 2025 at 3:01 PM
🧠 Alzheimer's Treatment Update: New drugs may cause brain swelling/bleeding
Anti-amyloid-β (Aβ) monoclonal antibodies like lecanemab and donanemab are shifting Alzheimer's treatment from symptom management to disease modification. They show modest slowing of cognitive decline in early AD.
1/2
Anti-amyloid-β (Aβ) monoclonal antibodies like lecanemab and donanemab are shifting Alzheimer's treatment from symptom management to disease modification. They show modest slowing of cognitive decline in early AD.
1/2
Europa cambia su evaluación y da un permiso restringido a lecanemab, el polémico fármaco contra el alzhéimer
Europa cambia su evaluación y da un permiso restringido a lecanemab, el polémico fármaco contra el alzhéimer
La Agencia Europea de Medicamentos da luz verde al uso de la medicina en ciertos casos, después de no autorizar el tratamiento para todos los pacientes
www.eldiario.es
November 14, 2024 at 5:53 PM
Europa cambia su evaluación y da un permiso restringido a lecanemab, el polémico fármaco contra el alzhéimer
Die EU hat erstmals eine Alzheimer-Therapie, Lecanemab, zugelassen, die auf Krankheitsursachen abzielt. Das Medikament verlangsamt den Verlauf im frühen Stadium, ist jedoch nur für eine kleine Patientengruppe geeignet und unterliegt strengen Auflagen.
Wirkstoff Lecanemab gegen Alzheimer zugelassen
Die Europäische Kommission hat erstmals eine Alzheimer-Therapie zugelassen, die auf zugrunde liegende Krankheitsprozesse abzielt. Der Antikörper Lecanemab sei für eine Behandlung im frühen Stadium und das erste Medikament dieser Art, das in der EU zugelassen werde, teilte die Kommission mit.
orf.at
April 15, 2025 at 6:48 PM
Die EU hat erstmals eine Alzheimer-Therapie, Lecanemab, zugelassen, die auf Krankheitsursachen abzielt. Das Medikament verlangsamt den Verlauf im frühen Stadium, ist jedoch nur für eine kleine Patientengruppe geeignet und unterliegt strengen Auflagen.